Cargando…

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease

Despite the availability of effective therapies that lower low‐density lipoprotein cholesterol (LDL‐C) levels in patients with atherosclerotic cardiovascular disease, many eligible patients are inadequately treated and their LDL‐C levels remain suboptimal. Patient nonadherence to lipid‐lowering ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Nihar R., Farbaniec, Michael, Karalis, Dean G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849440/ https://www.ncbi.nlm.nih.gov/pubmed/36267039 http://dx.doi.org/10.1002/clc.23935

Ejemplares similares

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
por: Faridi, Kamil F., et al.
Publicado: (2023)

Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia
por: Mszar, Reed, et al.
Publicado: (2023)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
por: Journath, Gunilla, et al.
Publicado: (2017)

A perspective on nonadherence to drug therapy: psychological barriers and strategies to overcome nonadherence
por: Martin, Leslie R, et al.
Publicado: (2018)

Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
por: Choi, Su-Yeon, et al.
Publicado: (2020)

Validity Of The Self-Reported Domains Of Subjective Extent Of Nonadherence (DOSE-Nonadherence) Scale In Comparison With Electronically Monitored Adherence To Cardiovascular Medications
por: Cornelius, Talea, et al.
Publicado: (2019)

Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence
por: Gupta, Pankaj, et al.
Publicado: (2017)

Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
por: Smith, Alex, et al.
Publicado: (2021)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Risk factors for drug nonadherence in antidepressant-treated patients and implications of pharmacist adherence instructions for adherence improvement
por: Murata, Atsunobu, et al.
Publicado: (2012)

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
por: Cannon, Christopher P., et al.
Publicado: (2021)

Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy
por: Citarella, Anna, et al.
Publicado: (2022)

Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses
por: Shaya, Fadia Tohme, et al.
Publicado: (2019)

Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease
por: Mahtta, Dhruv, et al.
Publicado: (2020)

Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study
por: Boretzki, Johanna, et al.
Publicado: (2017)

Nonadherence to immunosuppressives and treatment in kidney transplant: ADHERE BRAZIL Study
por: Marsicano-Souza, Elisa Oliveira, et al.
Publicado: (2021)

An Overview on Causes of Nonadherence in the Treatment of Rheumatoid Arthritis: Its Effect on Mortality and Ways to Improve Adherence
por: Chowdhury, Tutul, et al.
Publicado: (2022)

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
por: Karalis, Dean G., et al.
Publicado: (2012)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Barriers of Adherence and Possible Solutions to Nonadherence to Antidiabetic Therapy in Women with Diabetes in Pregnancy: Patients' Perspective
por: Mukona, Doreen, et al.
Publicado: (2017)

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States
por: Valero-Elizondo, Javier, et al.
Publicado: (2021)

Measures of Financial Hardship From Health Care Expenses Among Families With a Member With Atherosclerotic Cardiovascular Disease in the US
por: Wang, Stephen Y., et al.
Publicado: (2022)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011)

Clinical consequences of poor adherence to lipid-lowering therapy in patients with cardiovascular disease: can we do better?
por: Klimis, Harry, et al.
Publicado: (2019)

Intensity of and Adherence to Lipid‐Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease
por: Mazhar, Faizan, et al.
Publicado: (2022)

Patient-Reported Nonadherence with Glaucoma Therapy
por: Wolfram, Christian, et al.
Publicado: (2019)

Patient perceptions and use of non‐statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry
por: Lowenstern, Angela, et al.
Publicado: (2021)

Plasma Drug Level Validates Self-Reported Adherence but Predicts Limited Specificity for Nonadherence to Antiretroviral Therapy
por: Balikuddembe, Robert, et al.
Publicado: (2012)

Targeted Strategy in Lipid-Lowering Therapy
por: Dayar, Ezgi, et al.
Publicado: (2022)

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
por: Haddad, Peter M, et al.
Publicado: (2014)

Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
por: German, Charles Amir, et al.
Publicado: (2020)

Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study
por: Ersbøll, Annette Kjær, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on the management of risk factors in patients with stable atherosclerotic vascular disease
por: Karalis, Dean G., et al.
Publicado: (2023)

The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials
por: Daida, Hiroyuki, et al.
Publicado: (2019)

A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes
por: Mohan, Anjana, et al.
Publicado: (2023)

Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease
por: Power, Thomas P, et al.
Publicado: (2018)

Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year
por: Tran, Josephine N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vbt6iq0hfpgl9sssb6vtuac8a1